 Brian Lee
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 41 | 2023 | 238 | 5.910 |
Why?
| | Humans | 98 | 2023 | 6599 | 2.550 |
Why?
| | Child | 71 | 2023 | 3146 | 2.510 |
Why?
| | Respiratory Tract Infections | 8 | 2023 | 75 | 2.340 |
Why?
| | Hospitals, Pediatric | 16 | 2021 | 178 | 1.970 |
Why?
| | Retrospective Studies | 44 | 2023 | 1251 | 1.960 |
Why?
| | Enterovirus Infections | 3 | 2023 | 37 | 1.820 |
Why?
| | Picornaviridae Infections | 3 | 2023 | 20 | 1.790 |
Why?
| | Drug Utilization | 4 | 2020 | 13 | 1.720 |
Why?
| | Infant | 35 | 2023 | 1396 | 1.710 |
Why?
| | Hospitalization | 10 | 2023 | 192 | 1.700 |
Why?
| | Patient Readmission | 5 | 2023 | 66 | 1.680 |
Why?
| | Enterovirus | 2 | 2023 | 12 | 1.660 |
Why?
| | Parechovirus | 2 | 2023 | 19 | 1.640 |
Why?
| | Inappropriate Prescribing | 10 | 2023 | 27 | 1.590 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 28 | 1.450 |
Why?
| | Anti-Infective Agents | 7 | 2023 | 21 | 1.450 |
Why?
| | Child, Preschool | 34 | 2022 | 1459 | 1.300 |
Why?
| | Emergency Service, Hospital | 11 | 2023 | 129 | 1.290 |
Why?
| | Male | 42 | 2023 | 3197 | 1.270 |
Why?
| | Female | 41 | 2023 | 3436 | 1.220 |
Why?
| | United States | 24 | 2023 | 646 | 1.200 |
Why?
| | Ambulatory Care | 11 | 2022 | 46 | 1.160 |
Why?
| | Cross Infection | 4 | 2019 | 12 | 1.130 |
Why?
| | Inpatients | 4 | 2021 | 44 | 1.040 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2019 | 13 | 0.980 |
Why?
| | Practice Patterns, Physicians' | 10 | 2023 | 82 | 0.940 |
Why?
| | Rotavirus | 1 | 2023 | 11 | 0.930 |
Why?
| | Norovirus | 1 | 2023 | 7 | 0.930 |
Why?
| | Rotavirus Infections | 1 | 2023 | 15 | 0.920 |
Why?
| | Rotavirus Vaccines | 1 | 2023 | 13 | 0.920 |
Why?
| | Streptococcal Infections | 3 | 2022 | 19 | 0.910 |
Why?
| | Gastroenteritis | 1 | 2023 | 24 | 0.910 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.870 |
Why?
| | Adolescent | 29 | 2023 | 2087 | 0.830 |
Why?
| | Infant, Newborn | 18 | 2023 | 790 | 0.820 |
Why?
| | Pharyngitis | 4 | 2023 | 14 | 0.820 |
Why?
| | Hospital Mortality | 3 | 2023 | 21 | 0.810 |
Why?
| | Asthma | 5 | 2023 | 143 | 0.780 |
Why?
| | Drug Prescriptions | 5 | 2020 | 22 | 0.760 |
Why?
| | Patient Acuity | 1 | 2019 | 8 | 0.740 |
Why?
| | Pediatrics | 7 | 2020 | 170 | 0.720 |
Why?
| | Drug Eruptions | 1 | 2019 | 3 | 0.720 |
Why?
| | Risk Factors | 11 | 2023 | 460 | 0.720 |
Why?
| | Skin | 1 | 2019 | 13 | 0.710 |
Why?
| | Clostridium Infections | 1 | 2019 | 7 | 0.710 |
Why?
| | Ambulatory Care Facilities | 7 | 2023 | 38 | 0.690 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 9 | 0.680 |
Why?
| | Length of Stay | 10 | 2023 | 227 | 0.670 |
Why?
| | Medicaid | 4 | 2020 | 37 | 0.610 |
Why?
| | Listeriosis | 1 | 2016 | 1 | 0.560 |
Why?
| | Streptococcus agalactiae | 1 | 2016 | 1 | 0.560 |
Why?
| | Infection Control | 1 | 2016 | 7 | 0.560 |
Why?
| | Surveys and Questionnaires | 8 | 2023 | 290 | 0.550 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2021 | 36 | 0.540 |
Why?
| | Outpatients | 5 | 2023 | 28 | 0.540 |
Why?
| | Quality Improvement | 6 | 2021 | 60 | 0.490 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 44 | 0.490 |
Why?
| | Schools | 2 | 2023 | 49 | 0.460 |
Why?
| | Risk Adjustment | 2 | 2021 | 5 | 0.450 |
Why?
| | Otitis Media | 2 | 2023 | 5 | 0.450 |
Why?
| | Racism | 2 | 2022 | 8 | 0.430 |
Why?
| | Adult | 10 | 2022 | 1233 | 0.430 |
Why?
| | Pandemics | 2 | 2023 | 78 | 0.420 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2023 | 10 | 0.400 |
Why?
| | Databases, Factual | 7 | 2020 | 105 | 0.390 |
Why?
| | Prevalence | 6 | 2023 | 145 | 0.390 |
Why?
| | Urinary Tract Infections | 2 | 2023 | 17 | 0.390 |
Why?
| | Penicillins | 2 | 2022 | 8 | 0.390 |
Why?
| | Pharmacy Service, Hospital | 3 | 2020 | 8 | 0.370 |
Why?
| | Communication | 5 | 2022 | 54 | 0.360 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.360 |
Why?
| | Bacterial Infections | 2 | 2021 | 27 | 0.360 |
Why?
| | Cross-Sectional Studies | 9 | 2023 | 317 | 0.360 |
Why?
| | Influenza, Human | 2 | 2020 | 57 | 0.340 |
Why?
| | Cohort Studies | 6 | 2020 | 264 | 0.330 |
Why?
| | Drug Utilization Review | 3 | 2018 | 6 | 0.330 |
Why?
| | Internship and Residency | 2 | 2020 | 31 | 0.320 |
Why?
| | Bacteremia | 2 | 2019 | 25 | 0.310 |
Why?
| | Health Care Costs | 2 | 2019 | 29 | 0.310 |
Why?
| | Disease Outbreaks | 2 | 2023 | 30 | 0.300 |
Why?
| | Treatment Outcome | 6 | 2019 | 624 | 0.300 |
Why?
| | Child, Hospitalized | 3 | 2022 | 27 | 0.300 |
Why?
| | Guideline Adherence | 2 | 2018 | 33 | 0.290 |
Why?
| | Seasons | 2 | 2023 | 27 | 0.280 |
Why?
| | Aged | 4 | 2021 | 375 | 0.280 |
Why?
| | Incidence | 4 | 2023 | 125 | 0.270 |
Why?
| | Time Factors | 4 | 2020 | 241 | 0.270 |
Why?
| | Neoplasms | 2 | 2018 | 119 | 0.270 |
Why?
| | Giardiasis | 2 | 2018 | 2 | 0.270 |
Why?
| | Vaccination | 5 | 2022 | 68 | 0.260 |
Why?
| | Risk Assessment | 3 | 2019 | 130 | 0.260 |
Why?
| | Drug Hypersensitivity | 2 | 2022 | 19 | 0.260 |
Why?
| | Acute Disease | 5 | 2023 | 71 | 0.250 |
Why?
| | Chickenpox | 1 | 2004 | 1 | 0.250 |
Why?
| | Herpesvirus 3, Human | 1 | 2004 | 1 | 0.250 |
Why?
| | Chickenpox Vaccine | 1 | 2004 | 2 | 0.250 |
Why?
| | Curriculum | 2 | 2022 | 19 | 0.250 |
Why?
| | Young Adult | 6 | 2022 | 652 | 0.250 |
Why?
| | Wrist Injuries | 1 | 2023 | 1 | 0.240 |
Why?
| | Scaphoid Bone | 1 | 2023 | 1 | 0.240 |
Why?
| | Hand Injuries | 1 | 2023 | 3 | 0.240 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 7 | 0.240 |
Why?
| | Fractures, Bone | 1 | 2023 | 35 | 0.240 |
Why?
| | Otitis Media with Effusion | 1 | 2023 | 3 | 0.230 |
Why?
| | Feces | 1 | 2023 | 37 | 0.230 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 60 | 0.230 |
Why?
| | General Surgery | 2 | 2020 | 18 | 0.230 |
Why?
| | Students | 1 | 2023 | 43 | 0.230 |
Why?
| | Enterovirus D, Human | 1 | 2023 | 25 | 0.230 |
Why?
| | Liver Diseases | 1 | 2023 | 17 | 0.220 |
Why?
| | Vaccines | 1 | 2022 | 17 | 0.220 |
Why?
| | Pneumonia, Aspiration | 1 | 2022 | 8 | 0.210 |
Why?
| | Fever | 2 | 2019 | 26 | 0.210 |
Why?
| | Parents | 2 | 2021 | 149 | 0.210 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2019 | 15 | 0.210 |
Why?
| | Pneumonia | 1 | 2022 | 30 | 0.210 |
Why?
| | Patient Handoff | 1 | 2021 | 4 | 0.210 |
Why?
| | Osteomyelitis | 1 | 2021 | 6 | 0.210 |
Why?
| | Ceftriaxone | 1 | 2021 | 13 | 0.200 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 7 | 0.200 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 8 | 0.200 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 21 | 0.200 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 8 | 0.200 |
Why?
| | DNA, Viral | 1 | 2020 | 13 | 0.190 |
Why?
| | Point-of-Care Systems | 1 | 2020 | 15 | 0.190 |
Why?
| | Video Recording | 1 | 2020 | 14 | 0.190 |
Why?
| | Influenza A virus | 1 | 2020 | 20 | 0.190 |
Why?
| | Intestinal Polyposis | 1 | 2019 | 6 | 0.180 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2019 | 5 | 0.180 |
Why?
| | Colonic Polyps | 1 | 2019 | 5 | 0.180 |
Why?
| | Patient Education as Topic | 1 | 2020 | 64 | 0.180 |
Why?
| | Severity of Illness Index | 4 | 2023 | 142 | 0.180 |
Why?
| | Administration, Cutaneous | 1 | 2019 | 6 | 0.180 |
Why?
| | Missouri | 4 | 2023 | 78 | 0.180 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2019 | 20 | 0.180 |
Why?
| | Nurses | 2 | 2018 | 10 | 0.180 |
Why?
| | World Health Organization | 1 | 2019 | 5 | 0.180 |
Why?
| | Intubation, Gastrointestinal | 1 | 2019 | 18 | 0.180 |
Why?
| | Linear Models | 1 | 2019 | 55 | 0.180 |
Why?
| | Prospective Studies | 4 | 2022 | 508 | 0.180 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2019 | 31 | 0.180 |
Why?
| | Causality | 1 | 2019 | 10 | 0.170 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 4 | 0.170 |
Why?
| | Pharmacovigilance | 1 | 2019 | 8 | 0.170 |
Why?
| | Endoscopy | 1 | 2019 | 15 | 0.170 |
Why?
| | Cefazolin | 1 | 2018 | 2 | 0.170 |
Why?
| | Enteral Nutrition | 1 | 2019 | 62 | 0.170 |
Why?
| | Oseltamivir | 1 | 2018 | 6 | 0.170 |
Why?
| | Critical Pathways | 1 | 2018 | 9 | 0.170 |
Why?
| | Albuterol | 1 | 2018 | 5 | 0.170 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2018 | 2 | 0.170 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.170 |
Why?
| | Preoperative Care | 1 | 2018 | 25 | 0.170 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 8 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2018 | 11 | 0.170 |
Why?
| | Hospital Records | 1 | 2018 | 1 | 0.170 |
Why?
| | Rhinovirus | 1 | 2018 | 11 | 0.170 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 4 | 0.170 |
Why?
| | Disease Management | 1 | 2018 | 36 | 0.170 |
Why?
| | Anti-Asthmatic Agents | 1 | 2018 | 11 | 0.170 |
Why?
| | Patient-Centered Care | 1 | 2018 | 18 | 0.170 |
Why?
| | Prescription Drug Overuse | 1 | 2018 | 1 | 0.170 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 1 | 0.170 |
Why?
| | Psychometrics | 1 | 2018 | 33 | 0.170 |
Why?
| | Decision Making | 1 | 2018 | 34 | 0.170 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 9 | 0.170 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 32 | 0.170 |
Why?
| | Steroids | 1 | 2018 | 14 | 0.160 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2018 | 17 | 0.160 |
Why?
| | Health Communication | 1 | 2018 | 6 | 0.160 |
Why?
| | Survival Analysis | 1 | 2018 | 46 | 0.160 |
Why?
| | Information Dissemination | 1 | 2018 | 8 | 0.160 |
Why?
| | Nurse's Role | 1 | 2018 | 8 | 0.160 |
Why?
| | Bacteria | 1 | 2018 | 9 | 0.160 |
Why?
| | Logistic Models | 4 | 2019 | 91 | 0.160 |
Why?
| | Middle Aged | 5 | 2021 | 648 | 0.160 |
Why?
| | Electronic Health Records | 1 | 2018 | 61 | 0.160 |
Why?
| | Hepatitis C | 1 | 2017 | 4 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 50 | 0.160 |
Why?
| | Postoperative Complications | 1 | 2019 | 177 | 0.150 |
Why?
| | Hospitals | 3 | 2023 | 38 | 0.150 |
Why?
| | Substance-Related Disorders | 1 | 2017 | 32 | 0.150 |
Why?
| | Home Infusion Therapy | 1 | 2017 | 2 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2017 | 13 | 0.150 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 26 | 0.150 |
Why?
| | Antiviral Agents | 1 | 2017 | 26 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2017 | 17 | 0.150 |
Why?
| | Benchmarking | 3 | 2023 | 11 | 0.140 |
Why?
| | Health Information Systems | 1 | 2016 | 5 | 0.140 |
Why?
| | Pancreatitis | 1 | 2016 | 8 | 0.140 |
Why?
| | Streptococcus | 1 | 2016 | 2 | 0.140 |
Why?
| | Interdisciplinary Communication | 1 | 2016 | 9 | 0.140 |
Why?
| | Patient Transfer | 1 | 2016 | 8 | 0.140 |
Why?
| | Cardiology | 1 | 2016 | 11 | 0.140 |
Why?
| | Models, Theoretical | 1 | 2015 | 10 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 36 | 0.140 |
Why?
| | Health Education | 2 | 2020 | 39 | 0.140 |
Why?
| | Hospitalists | 1 | 2015 | 9 | 0.140 |
Why?
| | Medication Therapy Management | 1 | 2015 | 8 | 0.130 |
Why?
| | Minnesota | 3 | 2018 | 5 | 0.130 |
Why?
| | Acetamides | 1 | 2014 | 2 | 0.120 |
Why?
| | Oxazolidinones | 1 | 2014 | 2 | 0.120 |
Why?
| | Regression Analysis | 3 | 2019 | 56 | 0.120 |
Why?
| | Treatment Failure | 2 | 2022 | 17 | 0.120 |
Why?
| | Aged, 80 and over | 3 | 2021 | 150 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2021 | 80 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2019 | 197 | 0.110 |
Why?
| | Kansas | 2 | 2023 | 49 | 0.110 |
Why?
| | Primary Health Care | 3 | 2018 | 44 | 0.110 |
Why?
| | Prescriptions | 2 | 2022 | 10 | 0.110 |
Why?
| | Practice Guidelines as Topic | 3 | 2018 | 96 | 0.110 |
Why?
| | Reference Standards | 1 | 2021 | 15 | 0.100 |
Why?
| | Program Evaluation | 3 | 2020 | 52 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 145 | 0.100 |
Why?
| | Streptococcus pyogenes | 2 | 2022 | 13 | 0.090 |
Why?
| | Unsafe Sex | 1 | 2010 | 4 | 0.090 |
Why?
| | Homosexuality, Male | 1 | 2010 | 7 | 0.090 |
Why?
| | Safe Sex | 1 | 2010 | 5 | 0.090 |
Why?
| | Health Promotion | 1 | 2010 | 50 | 0.090 |
Why?
| | Age Distribution | 2 | 2019 | 31 | 0.090 |
Why?
| | Preventive Health Services | 1 | 2008 | 2 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2008 | 7 | 0.080 |
Why?
| | Hospital Charges | 2 | 2018 | 11 | 0.080 |
Why?
| | Comorbidity | 2 | 2019 | 61 | 0.080 |
Why?
| | Feedback | 2 | 2021 | 7 | 0.080 |
Why?
| | Child Health Services | 2 | 2020 | 24 | 0.080 |
Why?
| | HIV Infections | 1 | 2010 | 140 | 0.080 |
Why?
| | Mass Screening | 1 | 2008 | 41 | 0.080 |
Why?
| | Recurrence | 2 | 2017 | 115 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 16 | 0.070 |
Why?
| | Risk | 2 | 2016 | 40 | 0.070 |
Why?
| | Colorado | 2 | 2018 | 8 | 0.070 |
Why?
| | Health Care Surveys | 2 | 2019 | 32 | 0.060 |
Why?
| | Health Policy | 1 | 2004 | 13 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 53 | 0.060 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2023 | 3 | 0.060 |
Why?
| | Casts, Surgical | 1 | 2023 | 1 | 0.060 |
Why?
| | Mexico | 1 | 2023 | 6 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2018 | 315 | 0.060 |
Why?
| | Amoxicillin | 1 | 2023 | 4 | 0.060 |
Why?
| | Azithromycin | 1 | 2023 | 5 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 63 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 9 | 0.060 |
Why?
| | Prognosis | 1 | 2023 | 209 | 0.060 |
Why?
| | Bilirubin | 1 | 2023 | 25 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2023 | 29 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 14 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2022 | 3 | 0.060 |
Why?
| | Antibodies, Viral | 1 | 2022 | 46 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2022 | 43 | 0.050 |
Why?
| | Skin Tests | 1 | 2022 | 18 | 0.050 |
Why?
| | Cities | 1 | 2022 | 10 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2022 | 9 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2022 | 22 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2022 | 34 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 2 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 20 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 8 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 25 | 0.050 |
Why?
| | Pilot Projects | 1 | 2021 | 124 | 0.050 |
Why?
| | Patient Discharge | 1 | 2021 | 58 | 0.050 |
Why?
| | ROC Curve | 1 | 2020 | 18 | 0.050 |
Why?
| | Immunization | 1 | 2020 | 23 | 0.050 |
Why?
| | Leadership | 1 | 2020 | 9 | 0.050 |
Why?
| | Safety | 1 | 2020 | 14 | 0.050 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 7 | 0.050 |
Why?
| | Colonoscopy | 1 | 2019 | 15 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 33 | 0.050 |
Why?
| | Gastric Acidity Determination | 1 | 2019 | 1 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 10 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 10 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 104 | 0.040 |
Why?
| | Midwestern United States | 1 | 2019 | 39 | 0.040 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 13 | 0.040 |
Why?
| | Sepsis | 1 | 2019 | 22 | 0.040 |
Why?
| | Probability | 1 | 2019 | 17 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2019 | 14 | 0.040 |
Why?
| | Hospital Costs | 1 | 2019 | 27 | 0.040 |
Why?
| | Washington | 1 | 2018 | 11 | 0.040 |
Why?
| | Translations | 1 | 2018 | 5 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 17 | 0.040 |
Why?
| | Metered Dose Inhalers | 1 | 2018 | 1 | 0.040 |
Why?
| | Reimbursement, Incentive | 1 | 2018 | 4 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2018 | 26 | 0.040 |
Why?
| | Infant, Premature | 1 | 2019 | 81 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2018 | 32 | 0.040 |
Why?
| | Metabolic Diseases | 1 | 2018 | 11 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2018 | 41 | 0.040 |
Why?
| | Patient Participation | 1 | 2018 | 21 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 24 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2018 | 18 | 0.040 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 8 | 0.040 |
Why?
| | Home Care Services | 1 | 2018 | 7 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 19 | 0.040 |
Why?
| | Algorithms | 1 | 2019 | 103 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 45 | 0.040 |
Why?
| | Medical Records | 1 | 2018 | 14 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 32 | 0.040 |
Why?
| | Sex Factors | 1 | 2018 | 71 | 0.040 |
Why?
| | Urban Population | 1 | 2018 | 36 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2018 | 30 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 24 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 39 | 0.040 |
Why?
| | Rural Population | 1 | 2018 | 38 | 0.040 |
Why?
| | Health Resources | 1 | 2018 | 17 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2018 | 35 | 0.040 |
Why?
| | Research Design | 1 | 2018 | 64 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2017 | 13 | 0.040 |
Why?
| | Cost of Illness | 1 | 2018 | 19 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 62 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2018 | 202 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 40 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 92 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2018 | 64 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2017 | 2 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 7 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2017 | 5 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 17 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 10 | 0.040 |
Why?
| | Tablets | 1 | 2016 | 1 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2016 | 17 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 14 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 49 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 6 | 0.030 |
Why?
| | Linezolid | 1 | 2014 | 2 | 0.030 |
Why?
| | Data Collection | 1 | 2014 | 32 | 0.030 |
Why?
| | Food Parasitology | 1 | 2011 | 1 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 34 | 0.030 |
Why?
| | Population Surveillance | 1 | 2011 | 12 | 0.030 |
Why?
| | Diarrhea | 1 | 2011 | 18 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2011 | 12 | 0.030 |
Why?
| | Income | 1 | 2011 | 17 | 0.030 |
Why?
| | Risk-Taking | 1 | 2010 | 11 | 0.020 |
Why?
| | Insurance, Health | 1 | 2008 | 17 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|